Doctor of Osteopathy Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Tyler Menzies

Psychiatry Whitfield, MS Doctor of Osteopathy

NPI 1447991310 CMS profile 11635222

3550 Highway 468 W, Whitfield, MS 39193

Open in the dashboard

General payments

$2,901

109 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tyler Menzies of Whitfield, MS is reported in the CMS Open Payments database as having received $2,901 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,726 65
2024 General $1,175 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tyler Menzies
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Tyler Menzies were reported at $1,726. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Tyler Menzies Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $1,175 $179 $57–$673 $164
2025 $1,726 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Teva Pharmaceuticals USA, Inc. $638 22 payments
  2. Alkermes, Inc. $545 16 payments
  3. Neurocrine Biosciences, Inc. $452 20 payments
  4. Lundbeck LLC $262 11 payments
  5. Janssen Pharmaceuticals, Inc $249 11 payments
  6. E.R. Squibb & Sons, L.L.C. $219 10 payments
  7. AbbVie, Inc. $164 7 payments
  8. Otsuka America Pharmaceutical, Inc. $120 7 payments
  9. Vanda Pharmaceuticals Inc. $99 1 payment
  10. ITI, Inc. $87 1 payment
  11. Other $65 3 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $2,901 109 payments
Products named General payments · program years 2024–2025
  1. UZEDY $511 15 payments
  2. INGREZZA $452 20 payments
  3. LYBALVI $437 15 payments
  4. ARISTADA Cns $421 15 payments
  5. ARISTADA Cns $421 15 payments
  6. ARISTADA Cns $421 15 payments
  7. ARISTADA Cns $421 15 payments
  8. ABILIFY ASIMTUFII $342 16 payments
  9. INVEGA SUSTENNA $249 11 payments
  10. COBENFY $219 10 payments
  11. Other $1,129 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record